COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW. YHCĐ 2026, 67 (10). https://doi.org/10.52163/yhc.v67i10.6921.